Kornimate/medical-research-clean huggingface dataset:
mitraclip® after surgical mitral valve repair

Conditions: Mitral Regurgitation

Summary: percutaneous edge-to-edge repair of the mitral valve has been shown to be a safe and effective alternative treatment option for selected patients at high risk for cardiac surgery. patients with recurrent mitral regurgitation after surgical mitral valve repair (smvr) are per se at increased risk for another cardiac surgery. the purpose of this multicenter retrospective analysis of patients treated with a mitraclip® after smvr, is to evaluate the effectiveness and durability of this minimally invasive treatment option in this subset of patients.

in this multicenter retrospective analysis of mitraclip® cases after mvr the effectiveness and durability of this minimally invasive treatment option in this subset of patients will be evaluated.

Eligibility criteria:
inclusion criteria: * all patients with recurrent mitral regurgitation treated with a mitraclip®. exclusion criteria: * patient with endocarditis, * patients with torn mitral valve ring.
effectiveness of mirt on hand and finger dexterity in pd patients

Conditions: Parkinson Disease; Dexterity; Rehabilitation

Summary: aims of the study are (1) to evaluate the effectiveness of a specific ot treatment aimed to enhance finger and hand dexterity and (2) its impact on daily living autonomy of pd patients.

reduction in hand functionality and finger dexterity are significant, but often overlooked, symptoms of parkinson's disease (pd). they are strictly correlated with loss of patient's autonomy, due to their significant impact on activities of daily living (adl) and, consequently in patient's quality of life (qol). no studies investigated the effectiveness of a specific and functional-based occupational therapy (ot) treatment in improving hand functionality and finger dexterity in pd patients. aims of tthe study are to evaluate the effectiveness of a specific ot treatment aimed to enhance finger and hand dexterity and its impact on daily living autonomy of pd patients. retrospectively, 482 pd patients, hospitalized for a 4-week multidisciplinary intensive rehabilitation treatment (mirt) between january 2015 and january 2018 were identified. all patients underwent 1h/day ot treatment. the outcome measure was the o'connor finger dexterity test; secondary outcome measures were minnesota dexterity test, updrs ii and spdds scale. these measures were assessed at admission (t0) and discharge (t1).

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease exclusion criteria: * other neurological disease * psychosis * auditive or visual deficit
development and evaluation of effectiveness of an internet-based brief intervention for alcohol use among brazilian college students

Conditions: Alcohol Drinking

Summary: this project aims to develop and evaluate the effectiveness of an personalized normative feedback (pnf) intervention via the internet, through a randomized clinical trial for alcohol consumption among brazilian college students, as well as evaluating the most effective components of the pnf (normative and list of consequences). the sample is composed of college students aged between 18 and 30 years. participants allocated into four different groups: control, full intervention (pnf), feedback with normative components (fn) and feedback with list of consequences (flc). the investigators will use the dismantling design to study the most effective components. participants will be followed-up at 1, 3 and 6 months.


Eligibility criteria:
inclusion criteria: * college students * age 18-30 years * alcohol use during the last 3 months exclusion criteria: -
effect of an oral nutritional supplement on muscle mass during anticancer treatment

Conditions: Colorectal Cancer (CRC); Non-small Cell Lung Cancer (NSCLC)

Summary: malnutrition and low muscle mass (sarcopenia) are common problems in patients with cancer. however, a low muscle mass is associated with negative clinical outcomes in patients with cancer. therefore, it is very important to maintain muscle mass in this population. this study aims to investigate the effect of an oral nutritional supplement on skeletal muscle mass during anti-cancer treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of stage iii or iv colorectal or non-small cell lung cancer * scheduled for the first cycle of any line of a systemic treatment: chemotherapy, concurrent chemoradiotherapy, immunotherapy or targeted treatment with a planned duration of at least 9 weeks * performance status eastern cooperative oncology group (ecog) score 0 or 1 * age ≥ 18 years exclusion criteria: * weight loss \>10% in the last 6 months * body mass index \> 30.0 kg/m2 * life expectancy \< 3 months * receiving enteral (tube) or parenteral nutrition * presence of ileostoma or ileal pouch (except for an ileostomy at or near the terminal ileum which does not affect absorption of nutrients other than sodium, potassium, and water, in the opinion of the investigator) * allergy to cow's milk protein, soy or fish, requiring a fibre-free diet or suffering galactosemia or lactose intolerance * known pregnancy or lactation * current alcohol or drug abuse in the opinion of the investigator * wearing an electronic implant and/or pacemaker * investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements * participation in any other studies involving investigational or marketed products concomitantly or within 14 days prior to entry into the study

Keywords: muscle mass oral nutritional supplement colorectal cancer non-small cell lung cancer
additional measles vaccine at 4 months of age

Conditions: Measles Infection

Summary: overall objective: to conduct a randomised controlled trial (rct) to examine whether an early two-dose measles vaccination (mv) strategy at 4 and 9 months will reduce child mortality compared with the who strategy of one dose of mv at 9 months. specific hypotheses hypothesis i) two doses of mv at 4 and 9 months compared with the standard dose of mv at 9 months will reduce mortality by 30% between 4 months and 5 years of age1. as in a previous trial it is expected that the beneficial effect is strongest for girls. hypothesis ii) children receiving mv at 4 months in the presence of maternal measles antibodies (matab) will have 35% lower mortality between 4 months and 5 years of age than children receiving mv at 4 months with no detectable matab. implications: these hypotheses are based on a previous rct showing strong beneficial effects of providing an early measles vaccine, in particular among children with matab.


Eligibility criteria:
inclusion criteria: * children aged 4 to 7 months who received the third dose of pentavalent vaccine at least 4 weeks earlier exclusion criteria: * malformations * severely ill * severely malnourished

Keywords: mortality morbidity hospitalisations/consultations growth measles infection
methotrexate withdrawal study of tofacitinib modified release formulation in subjects with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg qd) versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to severe rheumatoid arthritis who are insufficiently responding to their stable dose of methotrexate treatment.


Eligibility criteria:
key inclusion criteria - must be 18 years of age or older. have a score of 6 or greater on the 2010 american college of rheumatology/european league against rheumatism classification criteria for rheumatoid arthritis at and/or prior to screening visit. * have ≥4 tender/painful joints on motion and ≥4 swollen joints (28 joint counts) at both screening visit and baseline visit (visit 1). * have moderate to severe disease activity as defined by cdai\>10 and das28-4(esr) ≥3.2 at baseline visit. * have taken an oral mtx treatment regimen (15-25mg/week) continuously for at least 4 months prior to the screening visit and has taken a stable weekly dose of oral mtx with supplemental folic acid or folinic acid for at least 4 weeks prior to the baseline visit (conversion from parenteral mtx to oral mtx will require stabilization of the treatment regimen for at least 1 month). * subjects must screen negative for active tuberculosis or inadequately treated tuberculosis infection (active or latent). key exclusion criteria * pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; male subjects able to father children and female subjects of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product. * subjects with infection or infection history; subjects with any current malignancy or a history of malignancy (except adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ); subjects with history of, or current evidence for, severe gastrointestinal narrowing (pathologic or iatrogenic); and subjects with history of documented diverticulitis. * subjects with a history of insufficient response to ≥2 biologics, regardless of the class.

Keywords: rheumatoid arthritis tofacitinib cp-690,550 xeljanz methotrexate withdrawal withdrawal study
acceptance and commitment therapy and compassion-based virtual group therapy to improve psychological wellbeing in patients with cancer

Conditions: Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm

Summary: this clinical trial tests how well acceptance and commitment therapy and compassion based virtual group therapy works to improve psychological wellbeing, such as compassion, understanding, and flexibility, in patients with cancer. receiving a cancer diagnosis, undergoing cancer treatment, and living with cancer- or treatment-related symptoms have often been found to be associated with elevated distress and decreased quality of life for individuals, even when the disease is stable or in remission. acceptance and commitment therapy (act) has demonstrated considerable benefits on individuals' quality of life, psychological flexibility, and amelioration of psychological distress following a cancer diagnosis and in the face of uncertainty, loss, and challenges associated with cancer.

primary objectives: i. to assess if participants perceive compassion and understanding by the provider who facilitates the virtual group intervention. ii. to assess if participation in the act-based group intervention is associated with increases in patients' self-reported psychological flexibility as well as amelioration in psychological and physical distress. secondary objective: i. to assess if participation in the act-based group intervention is associated with increases in patients' self-reported mindfulness, self-compassion, meaning and purpose, and posttraumatic growth. outline: patients attend acceptance and commitment virtual group therapy sessions over 1.5 hours each, once a week for 6 weeks. after completion of study treatment, patients are followed up at 1 month.

Eligibility criteria:
inclusion criteria: * being an adult (18 years or older) * being a patient of mayo clinic arizona * having a cancer diagnosis, having treatment planning in progress, undergoing cancer-related treatment, or having completed cancer within the past 2 years (in recent survivorship * experiencing stress or challenges related to cancer and having treatment goals that align with the purpose of the group * having self reported proficiency to read/write/speak english * expressing interest and commitment to attend all six virtual group sessions exclusion criteria: * patients' inability to take part in and benefit from the virtual group therapy based on clinical judgment of the psychosocial oncology team member who completes the psychosocial evaluation, which may include having active suicidal or homicidal intent, experiencing uncontrolled psychotic symptoms, having untreated personality disorder/characteristics that are likely disturbing in a group setting, and/or having moderate to severe cognitive impairments
effects of remimazolam and propofol on anesthesia induction

Conditions: Diabetes

Summary: the patients with diabetes who underwent laparoscopic cholecystectomy in the general surgery department of the second hospital of shanxi medical university were selected. the patients who were induced by remimazolam were included in the experimental group, and the patients who were induced by propofol were included in the control group. all the selected patients had no intimate relationship. the differences of blood pressure, heart rate and heart rate variability (hrv) between the experimental group and the control group were observed. according to the literature, it is speculated that the changes of blood pressure, heart rate and hrv indexes in the experimental group are smaller than those in the control group, and the difference is statistically significant.


Eligibility criteria:
inclusion criteria: * diagnosed as type 2 diabetes according to the "chinese guidelines for the prevention and treatment of type 2 diabetes 2020" * asa ii or iii exclusion criteria: * people who are allergic to remimazolam * it is estimated that patients with difficulty in tracheal intubation (poor head and neck mobility, history of airway surgery, history of osahs, nail to chin distance\ 30kg · m-2), etc * hypertension (clinically diagnosed as hypertension) * patients with coronary heart disease (with typical symptoms of angina pectoris and exclusion of aortic valve disease, clear history of old myocardial infarction, clear history of acute myocardial infarction, coronary stenosis greater than or equal to 70% found by cag) * patients with arrhythmia, heart failure, renal failure, and recently taking cardiovascular active drugs * endocrine diseases such as hyperthyroidism and pheochromocytoma that may affect the level of body hemodynamics * ketoacidosis and lactic acidosis * patients with long-term use of sedatives or antidepressants or a history of alcoholism or drug dependence * asthma or reactive airway disease * patients with myasthenia gravis and cognitive dysfunction cannot cooperate with this study
comparison of the effects of kinesiotape application and foam roller exercises

Conditions: Low Back Pain, Mechanical

Summary: low back pain is an important health problem that is common worldwide, with a lifetime prevalence of up to 80%.

low back pain that lasts less than 6 weeks is called acute low back pain, if it continues for 6-12 weeks it is called subacute low back pain, and if it continues for more than 12 weeks it is called chronic low back pain. the majority of low back pain (97%) is of mechanical origin.

Eligibility criteria:
inclusion criteria: * patients with chronic low back pain * individuals aged 18-60 years * patients without verbal communication barriers * patients without cognitive impairment (delirium, dementia, amnesia) exclusion criteria: * exercise contraindication (uncontrolled medical conditions) * patients with previous spinal surgery * patients who develop an allergic reaction to the kinesiotape tape to be applied
autologous human adipose-derived mesenchymal stem cells in alzheimer's disease

Conditions: Alzheimer Disease

Summary: this is a single patient emergency expanded access clinical study to assess the safety of administering autologous admscs to an incurable alzheimer disease patient. the study subject will be evaluated for disease-associated severity according to symptoms, cognitive function, memory, and quality of life.


Eligibility criteria:
inclusion criteria: * the patient is diagnosed with later stage of alzheimer disease with sever cognitive disability. * all current anti-alzheimer medicines cannot prevent disease progression and the patient's mental and physical ability persistently declined * patient's legal guardian and caregiver must voluntarily sign an approved written consent form after ample explanation of the proposed therapy. exclusion criteria: * current diagnosis of malignancy * renal/liver dysfunction: exceed two times as normal subject * pregnant or nursing * received other trial drugs within 30 days after participation of this study * experienced major surgery or trauma in the last 14 days

Keywords: autologous adipose-derived stem cells (admscs)
study of the relative oral bioavailability of the antiflu medicine oseltamivir in the intensive care unit

Conditions: Influenza A Virus Infection; Influenza B Virus Infection

Summary: this proposed pharmacokinetic study will test the hypothesis that in critically ill patients with respiratory failure requiring mechanical ventilation such as might be anticipated to be needed to treat patients with severe influenza pneumonia, oseltamivir administered enterally via nasogastric tube, with and without concomitant food or alimentation, will have similar oral bioavailability to that observed in ambulatory adults ill with influenza in whom oseltamivir therapy 75 mg bid is efficacious and well tolerated. additionally, this experiment will test the hypothesis that increasing the dose (150 mg), with and without concomitant enteral feeding, will show a proportionate increase in bioavailability. relative oral bioavailability will be assessed from plasma concentration vs. time over 12 hrs and urinary recovery of drug from 0 to 48 hrs after administration.

not required

Eligibility criteria:
inclusion criteria: * patients admitted to the intensive care unit requiring mechanical ventilation due to respiratory failure * must be within the ages of 18-75 yrs exclusion criteria: * patients unable to have enteral feeding * intolerance to oseltamivir * pregnancy * gastrointestinal or malabsorptive disease * intestinal bypass surgery * diarrhea (\>2 loose bowel movements per day) * receipt of prokinetic medications (metoclopramide, domperidone, erythromycin) * severe liver disease (hepatocellular enzymes \> 3 times the upper limit of normal) * renal failure (cockroft-gault creatinine clearance \< 30 ml/min, dialysis dependant) * cystic fibrosis * intoxication or drug overdose

Keywords: prevention or treatment of influenza in ventilated patients
comparative study between oxytocin infusion before and after placental delivery on blood loss during and after cesarean delivery .

Conditions: Intraoperative Blood Loss

Summary: participants were randomized using computer-generated random numbers into 2 groups. group i included 32 women who received oxytocin infusion before placental delivery just after cord clamping and group ii included 32 women who received oxytocin infusion after placental delivery. in both groups 10 iu of oxytocin (syntocinon, novartis, basel, switzerland) were diluted in 500 ml of normal saline and administered through intravenous infusion over 30 minutes.

participants were randomized using computer-generated random numbers into 2 groups. group i included 32 women who received oxytocin infusion before placental delivery just after cord clamping and group ii included 32 women who received oxytocin infusion after placental delivery. in both groups 10 iu of oxytocin (syntocinon, novartis, basel, switzerland) were diluted in 500 ml of normal saline and administered through intravenous infusion over 30 minutes.

Eligibility criteria:
inclusion criteria: * age 18 - 40 years * singleton full term pregnancy. * candidate for elective cesarean delivery under spinal anaesthesia exclusion criteria: * women at high risk for intraoperative bleeding as those with placenta previa or other placental abnormalities * women with bleeding or coagulation disorders. * medical disorder associating pregnancy as preeclampsia or diabetes * allergy or contraindications to oxytocin * fetal macrosomia, or congenital anomalies * polyhydramnios * uterine abnormalities as fibroids * women with intraoperative complications as vascular or visceral injuries
investigating the feasibility and outcomes of patient self-drain removal after ventral hernia repair

Conditions: Ventral Hernia

Summary: the goal of this randomized controlled trial is to teach patients to safely and effectively self-remove drains at home in adults (aged 18 and older) following a ventral hernia repair (vhr). researchers will compare the group of subjects self-removing the drain at home to a control group of standard of care drain removal during a clinic visit by a provider to see if subjects are able to safely self-remove the drain at home.

annually, in the united states, it is estimated that 500,000 ventral hernia repairs (vhrs) are performed with a cost in excess of $3.2 billion. drains are frequently used in an effort to prevent seroma formation. seromas are defined as a buildup of bodily fluid in a potential space post-surgery, usually at the surgical site. rate of seroma has been estimated to be between 9-11% following abdominal wall reconstruction (awr). the timing of the removal is usually after discharge but before patient's scheduled postoperative visit, thus most patients must call and speak to a health provider and come in for an additional clinic visit specifically for drain removal. the goal of this study is to teach patients to safely and effectively self-remove drains at home. this will allow patients to forgo the cost associated with commuting to the clinic, the clinic cost associated with nursing time and scheduling, the clinic visit, physician or nurse time to remove the drain and possibly lost wages for the patient from time off work. it is important to note that self-drain removal will not compromise or deviate from typical patient follow up. instead, this will eliminate an extra patient visit when inevitably the timing of drain removal does not align with the typical follow-up period. additionally, this will allow providers to see additional patient consultations or perform other duties, as they will not have the time constraints associated with in-office drain removal. this study will show that patient self-drain removal benefits the patients, the providers, and healthcare system without compromising patient safety, satisfaction, and postoperative care.

Eligibility criteria:
inclusion criteria: * aged ≥18 years. * undergoing elective ventral hernia repair (vhr). * sub-cutaneous drain placement. * anticipated centers for disease control and preventions (cdc) 1\&2 wound class. exclusion criteria: * patients who do not have access to the online training video. * the surgeon does not believe the patient can self-remove the drain. * planned concomitant procedures. * current mesh infection.

Keywords: hernia repairs drain removal subcutaneous drains